JP2012515213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515213A5 JP2012515213A5 JP2011546329A JP2011546329A JP2012515213A5 JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5 JP 2011546329 A JP2011546329 A JP 2011546329A JP 2011546329 A JP2011546329 A JP 2011546329A JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- individual
- combination
- antigen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14453709P | 2009-01-14 | 2009-01-14 | |
| US61/144,537 | 2009-01-14 | ||
| US29309610P | 2010-01-07 | 2010-01-07 | |
| US61/293,096 | 2010-01-07 | ||
| PCT/US2010/021029 WO2010083298A1 (en) | 2009-01-14 | 2010-01-14 | Methods and compositions containing mtor inhibitors for enhancing immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515213A JP2012515213A (ja) | 2012-07-05 |
| JP2012515213A5 true JP2012515213A5 (enExample) | 2012-12-27 |
Family
ID=42340082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546329A Pending JP2012515213A (ja) | 2009-01-14 | 2010-01-14 | 免疫応答を増強するための、ｍＴＯＲ阻害剤を含有する方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100196311A1 (enExample) |
| EP (1) | EP2375897A4 (enExample) |
| JP (1) | JP2012515213A (enExample) |
| CN (1) | CN102281761A (enExample) |
| CA (1) | CA2748931A1 (enExample) |
| WO (1) | WO2010083298A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| AU2014348657A1 (en) * | 2013-11-13 | 2016-05-19 | Novartis Ag | mTOR inhibitors for enhancing the immune response |
| WO2015120198A1 (en) | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| CA2986359A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| ES3009356T3 (en) | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| CN107921050A (zh) * | 2015-06-29 | 2018-04-17 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法 |
| US10624925B2 (en) | 2015-07-20 | 2020-04-21 | Mayo Foundation For Medical Education And Research | Methods and materials for producing T cells |
| JP7653759B2 (ja) * | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| SG11201805186VA (en) | 2016-01-20 | 2018-07-30 | Fate Therapeutics Inc | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| EP3548049A4 (en) * | 2016-12-05 | 2020-07-22 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| CN110412289B (zh) * | 2019-07-25 | 2022-08-02 | 北京美迪阿姆科技发展有限公司 | 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用 |
| CN114426952A (zh) * | 2020-10-29 | 2022-05-03 | 中国科学技术大学 | 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999048524A1 (en) * | 1998-03-03 | 1999-09-30 | University Of Southern California | Use of cytokines and mitogens to inhibit graft versus host disease |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| WO2003038062A2 (en) * | 2001-10-31 | 2003-05-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Generation of use of tc1 and tc2 cells |
| US7718196B2 (en) * | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
| WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| ATE353954T1 (de) * | 2002-10-11 | 2007-03-15 | Sentoclone Therapeutics Ab | Immuntherapie für krebs |
| CA2529244C (en) * | 2003-06-12 | 2014-02-18 | The Trustees Of The University Of Pennsylvania | Rapamycin resistant t cells and therapeutic uses thereof |
| US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| US8119772B2 (en) * | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| WO2008134879A1 (en) * | 2007-05-04 | 2008-11-13 | University Health Network | Il-12 immunotherapy for cancer |
| CA2733203A1 (en) * | 2008-08-05 | 2010-02-11 | Emory University | Use of mtor inhibitors to enhance t cell immune responses |
-
2010
- 2010-01-14 EP EP10732083.0A patent/EP2375897A4/en not_active Withdrawn
- 2010-01-14 US US12/687,650 patent/US20100196311A1/en not_active Abandoned
- 2010-01-14 WO PCT/US2010/021029 patent/WO2010083298A1/en not_active Ceased
- 2010-01-14 JP JP2011546329A patent/JP2012515213A/ja active Pending
- 2010-01-14 CA CA2748931A patent/CA2748931A1/en not_active Abandoned
- 2010-01-14 CN CN2010800048759A patent/CN102281761A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515213A5 (enExample) | ||
| Khosravi et al. | Immunologic tumor microenvironment modulators for turning cold tumors hot | |
| Yang et al. | Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment | |
| Liu et al. | Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond | |
| Wang et al. | Modulation of gut microbiota: a novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy | |
| Dallenga et al. | Neutrophils in tuberculosisâ   first line of defence or booster of disease and targets for host-directed therapy? | |
| Chen et al. | Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients | |
| JP2015134813A5 (enExample) | ||
| JP2019512020A5 (enExample) | ||
| US20200323905A1 (en) | Methods and compositions for modulating the immune system | |
| Zou et al. | Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer | |
| Chandwaskar et al. | Dysregulation of T cell response in the pathogenesis of inflammatory bowel disease | |
| Pai et al. | Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels | |
| Qi et al. | P. aeruginosa mediated necroptosis in mouse tumor cells induces long-lasting systemic antitumor immunity | |
| Gras et al. | The inhibition of Th17 immune response in vitro and in vivo by the carbosilane dendrimer 2G-NN16 | |
| Yue et al. | Harnessing CD8+ T cell dynamics in hepatitis B virus‐associated liver diseases: Insights, therapies and future directions | |
| Madan et al. | Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells | |
| Nobel et al. | STAT signaling in the intestine | |
| Xiong et al. | Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor | |
| US20160067272A1 (en) | Methods for treating immune diseases | |
| Huart et al. | Could protons and carbon ions be the silver bullets against pancreatic cancer? | |
| Callejas et al. | Interleukin-4 programmed macrophages suppress colitis and do not enhance infectious-colitis, inflammation-associated colon cancer or airway hypersensitivity | |
| Chen et al. | Irradiated whole-cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells | |
| Wang et al. | Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor | |
| Wu et al. | Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model |